Anti Vegf Eylea 2mg denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for anti vegf eylea 2mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denied Eylea (aflibercept 2 mg) for Exceeding Quantity Limits

A quantity-limit denial means UHC's system has approved Eylea 2 mg injections up to a set frequency or annual count — defined in UHC's published quantity-limit policy for anti-VEGF agents — and your prescriber is requesting a treatment schedule that exceeds that limit. For retinal conditions, treat-and-extend or monthly injection schedules sometimes exceed default limits designed around a loading-phase assumption. The denial does not mean the drug is inappropriate; it means the plan needs additional justification to authorize treatment beyond its default frequency.

## Why This Denial Is Appealable

Quantity limits are plan defaults, not clinical maxima. For active retinal disease, the treating ophthalmologist determines the medically appropriate injection interval based on individual response — a clinical judgment that a blanket quantity limit cannot substitute for. The appeal must demonstrate that the requested frequency is supported by objective disease activity in the chart and is consistent with the FDA-approved prescribing information and applicable retinal specialty guidelines. UHC's quantity-limit policy itself typically includes an exception pathway for documented clinical need.

## Your Federal Appeal Rights

• Quantity-limit exception: Request this before filing a formal appeal; it may be resolved faster at the medical-policy level.
• Internal appeal (ERISA §503 / ACA): File within the deadline on your denial letter. UHC must conduct a full review of the clinical justification for the requested quantity.
• External review (ACA §2719): If the internal appeal is denied, escalate to an IRO within approximately four months. Quantity-limit denials grounded in a medical-necessity determination are eligible for external review.
• Expedited review: Available when delay would seriously jeopardize your vision.

## Documentation to Gather

1. Injection log — a complete record of all prior Eylea and anti-VEGF injections with dates, documenting the treatment history that led to the current dosing schedule. 2. Objective disease-activity evidence — OCT images and reports from each visit showing fluid levels, central subfield thickness trends, or other markers your retinal specialist uses to determine injection timing. 3. Prescriber justification letter — your retinal specialist must explain why the requested frequency is medically necessary for this patient's disease activity, referencing the FDA-approved label's guidance on dosing flexibility and applicable AAO or vitreoretinal society guidelines (by organization name). 4. Visual acuity trend — serial BCVA measurements demonstrating how treatment frequency correlates with functional outcomes. 5. UHC quantity-limit policy — obtain the current published policy; identify the exception criteria and address each in the prescriber's letter.

## Criteria-Mapping Structure

Your appeal should present the quantity-limit exception criteria from UHC's policy in a table, with the matching chart evidence beside each criterion. The decisive entries are typically the objective imaging findings that demonstrate ongoing disease activity requiring treatment at the requested interval — not merely physician preference, but documented necessity tied to measurable findings.